Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Hematopoietic Growth Factor PIXY321 After Moderate-Dose Fluorouracil, Doxorubicin, and Cyclophosphamide in Stage II and III Breast ...
Nomogram to predict risk of 30-day mortality for patients with disseminated malignancy undergoing surgical intervention. Background: There is wide variability in the treatment of metastatic breast ...
Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases. Recent advances in targeted therapies and immunotherapies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback